All Oncology News

David A. Braun, MD, PhD, discusses the need for more tailored treatments that improve tumor-specific T-cell infiltration in chromophobe RCC.

Retrospective data showed CAR T-cell therapy is feasible in patients with aggressive lymphomas and active autoimmune diseases.

The antibody-drug conjugate SHR-A1811 demonstrated a comparable pCR rate to SHR-A1811/pyrotinib and PCbHP in HER2-positive breast cancer.

Ruby Arora, MD, discusses an analysis of SEER data on the declining MCL incidence and disparities that persist in Hispanic and American Indian patients.

Neoadjuvant vidutolimod plus pembrolizumab showed promising activity in stage III resectable melanoma.

HLD-0915 has received fast track designation from the FDA, allowing for more frequent communication with the agency regarding the drug’s candidacy for approval.

Huntsman Cancer Institute is expanding its proton therapy center, enhancing access to advanced cancer treatment for patients in the Mountain West region.

Sonam Puri, MD, discusses advances in small cell lung cancer that have expanded treatment options across disease stages.

David A. Braun, MD, PhD, outlines differences in the tumor biology and immune phenotypes of chromophobe and clear cell renal cell carcinoma.

Sigvotatug vedotin is being compared with docetaxel in patients with pretreated NSCLC in the phase 3 Be6A Lung-01 study.

Treatment with the combination of anlotinib and toripalimab produced durable efficacy in soft tissue sarcoma and bone sarcoma.

Genetic testing could help determine differences between rare forms of kidney cancer.

CD19 t-haNK demonstrated complete responses in 2 patients with heavily pretreated Waldenstrom macroglobulinemia.

Perioperative pembrolizumab has received the green light for use in combination with radiotherapy with or without cisplatin in PD-L1–positive HNSCC.

Real-world tucatinib-based regimens were effective in different lines for HER2-positive metastatic breast cancer, including after trastuzumab deruxtecan.

Zeynep Eroglu, MD, discusses the potential PFS benefit with encorafenib plus binimetinib and nivolumab in BRAF V600–mutant melanoma with symptomatic brain metastases.

Dalpiciclib plus pyrotinib and endocrine therapy was active with a manageable safety profile in patients with ER-positive, HER2-positive advanced breast cancer.

Real-world data supported the clinical effectiveness of first-line palbociclib plus endocrine therapy in HR-positive, HER2-negative breast cancer.

Domenica Lorusso, MD, PhD, discusses the use of relacorilant plus nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer.

Insights into sarcomatoid renal cell carcinoma point to broader use of common immunotherapies.

The FDA has cleared iPETcertum for PET and PET-CT/MRI scan enhancement in patients with cancer and suspicious lesions.

Perioperative enfortumab vedotin plus pembrolizumab significantly extended survival vs surgery alone in MIBC.

Tanios S. Bekaii-Saab, MD, discusses evolving frontline and evolving treatment strategies in esophageal cancer, HCC, and NETs.

Krzysztof Jamroziak, MD, PhD, discusses the feasibility of MRD-guided, early intervention with daratumumab in patients with multiple myeloma.

Andrew Kuykendall, MD, discusses the evolving role of BTK inhibitors, as well as emerging targets and treatment modalities targeting BTK and BCL2 in CLL.

Extended follow-up showed sintilimab plus anlotinib yielded durable efficacy and tolerability in PD-L1–positive recurrent/metastatic cervical cancer.

Tanios S. Bekaii-Saab, MD, discusses sequencing approaches in metastatic pancreatic cancer and colorectal cancer.

Dana-Farber Cancer Institute researchers have developed a blood test that could help transform the diagnosis and monitoring of multiple myeloma.

The off-the-shelf therapeutic cancer vaccine plus pembrolizumab improved PFS vs pembrolizumab alone in advanced melanoma.

The FDA has approved the Oncomine Dx Target Test as a companion diagnostic for zongertinib in NSCLC harboring HER2 TKD mutations.